Ocumetics Technology Corp. Announces Successful Completion of Key Clinical Milestones and Updates on Group Two First-in-Human Surgeries

Calgary, Alberta — November 12, 2026 — Leads & Copy — Ocumetics Technology Corp. announced the successful completion of key clinical milestones for its advanced ophthalmic technology, marking a significant step towards the Group Two first-in-human surgeries. The company is approaching patient lens implantations for Group Two, with all clinical, regulatory, and manufacturing requirements now finalized.

Dean Burns, CEO of Ocumetics, expressed excitement about reaching this value-defining milestone. The company is currently finalizing details for the imminent patient lens implantations.

Burns stated that if the Group Two patient results meet or exceed objectives, similar to the Group One results, prior discussions with major global ophthalmic companies can progress to the next stage. Initial patient results are anticipated by the end of the year, with data to advance potential negotiations expected in early 2027.

The Group Two lens implantations will focus on studying the safety, distance, and near vision performance of the Ocumetics accommodating intraocular lens, a departure from the Group One study's primary focus on safety.

Over recent months, Ocumetics has achieved several critical clinical, regulatory, and manufacturing milestones. These include the manufacturing and testing of a redesigned, next-generation Ocumetics Lens incorporating engineering advancements for enhanced performance, surgical handling, reliability, and manufacturing scalability. The company also confirmed the Mexico City clinic for Group Two patient lens implantations and delivered redesigned lens delivery systems to the site.

Additionally, enhanced Group Two clinical protocols were submitted to the clinic ethics committee, confirming the study will evaluate the Ocumetics Lens for safety, near-vision, and distance-vision performance. Patient recruitment at the Mexico City clinical site has commenced, alongside the evaluation of 12-month visit results from the Group One study.

Upcoming clinical activities include final site initiation and surgeon training immediately preceding the Group Two Ocumetics Lens implantations, followed by the procedures themselves. Patients will undergo daily, weekly, and monthly progress monitoring. Reporting on the results of the Group One twelve-month follow-up visits is expected shortly.

Ocumetics Technology Corp. is a Canadian research and product development company focused on creating advanced vision correction solutions. The company is currently in the early feasibility study phase of a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. This lens aims to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag.

Source: Ocumetics Technology Corp.